ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC. (ZVRA)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue, net | NaN | 34,125 | NaN | NaN |
| Research and development directly identified to programs-Direct Operating Costs | NaN | 1,230 | NaN | NaN |
| Research and development directly identified to programs-Indirect Operating Costs | NaN | 1,390 | NaN | NaN |
| Selling, general and administrative identified to programs-Direct Operating Costs | NaN | 7,611 | NaN | NaN |
| Selling, general and administrative identified to programs-Indirect Operating Costs | NaN | 12,743 | NaN | NaN |
| Impairment of intangible assets | NaN | 0 | NaN | NaN |
| Income tax expense | NaN | 6,397 | NaN | NaN |
| Interest income | NaN | 2,265 | NaN | NaN |
| Depreciation and amortization expense | NaN | 362 | NaN | NaN |
| Interest expense | NaN | 1,948 | NaN | NaN |
| Other (income) expense, net | NaN | -265,910 | NaN | NaN |
| Net income (loss) | 37,890 | 12,165 | -544 | 71,608 |
| Stock-based compensation expense | 3,105 | 4,284 | 2,771 | 5,579 |
| Non-cash interest expense | NaN | 612 | 685 | 1,352 |
| Impairment of intangible assets | NaN | 0 | 0 | 58,710 |
| Inventory write-down | 485 | 0 | 0 | 11,681 |
| Income tax expense | 6,914 | 501 | -433 | 3,381 |
| Depreciation and amortization expense | 368 | 362 | 392 | 3,300 |
| Non-cash interest expense | 341 | NaN | NaN | NaN |
| Gain on sale of prv | NaN | NaN | 0 | 148,325 |
| Non-cash lease expense | 118 | 602 | NaN | NaN |
| Fair value adjustment related to warrant and cvr liability | -968 | -3,557 | 5,506 | -4,127 |
| Accretion on investments | 624 | 857 | 1,211 | 1,060 |
| Fair value adjustment related to investments | 216 | -30 | -124 | 5 |
| Loss on extinguishment of debt | -2,756 | NaN | NaN | NaN |
| Loss on derivative liability | -7,216 | NaN | NaN | NaN |
| Cash paid to settle derivative instrument and payoff premium | 9,016 | NaN | NaN | NaN |
| Settlement of royalties to aquestive | -4,393 | NaN | NaN | NaN |
| Paid-in-kind interest | 3,134 | NaN | NaN | NaN |
| Loss on sublease and disposal of property and equipment | NaN | 63 | NaN | NaN |
| Gain on sale of future royalties, intellectual property, and other assets, net | 43,314 | 148,325 | NaN | NaN |
| Consulting fees paid in common stock | 0 | 0 | 0 | 75 |
| (gain) loss on foreign currency exchange rates | 1,403 | -1,422 | 5 | -131 |
| Accounts and other receivables | -6,890 | 6,367 | -1,359 | 6,969 |
| Prepaid expenses and other current assets | -2,053 | -399 | 3,046 | 296 |
| Inventories | 185 | 525 | 194 | 586 |
| Operating lease right-of-use assets | 476 | NaN | -1,274 | 798 |
| Other long-term assets | 87 | -451 | NaN | NaN |
| Accounts payable and accrued expenses | -529 | 412 | -4,730 | -11,269 |
| Discount and rebate liabilities | 1,150 | 2,166 | 1,469 | 3,048 |
| Operating lease liabilities | -123 | -129 | -1,292 | 746 |
| Other liabilities | 416 | -5,982 | 2,832 | 1,991 |
| Net cash provided by (used in) operating activities | 6,142 | 5,516 | 4,709 | -11,823 |
| Sale of future royalties, intellectual property, and other assets, net | 43,935 | NaN | NaN | NaN |
| Purchases of property and equipment | 35 | -31 | 554 | 312 |
| Disposals of property and equipment | 42 | -141 | 589 | NaN |
| Proceeds from sale of prv | NaN | 0 | 0 | 150,000 |
| Purchases of investments | 58,296 | 87,163 | 65,111 | 157,712 |
| Payment of royalty to xoma | NaN | 0 | NaN | NaN |
| Sales and maturities of investments | 93,972 | 87,500 | 60,500 | 30,500 |
| Proceeds from issuance of stock | NaN | 0 | 0 | NaN |
| Net cash provided by investing activities | 79,618 | 227 | -4,576 | 22,476 |
| Proceeds from issuance of common stock for options exercised | NaN | 235 | NaN | 2,947 |
| Proceeds from insurance financing arrangements | NaN | 0 | 0 | 0 |
| Proceeds from employee stock purchase plan | NaN | 202 | 0 | 413 |
| Proceeds from issuance of debt, net of lender fees | NaN | NaN | 0 | 0 |
| Payment of third-party debt issuance costs | NaN | NaN | 0 | 0 |
| Proceeds from issuance of debt, net of lender fees | NaN | 0 | NaN | NaN |
| Repayment of debt | 60,092 | 0 | 0 | 0 |
| Payments for employee taxes related to stock awards | 2,635 | NaN | NaN | NaN |
| Proceeds from issuance of common stock for options exercised | -2,768 | NaN | 3,520 | NaN |
| Proceeds from issuance of common stock for warrants exercised | 9,171 | 2,682 | 5,957 | NaN |
| Payments of principal on insurance financing arrangements | 0 | 0 | 0 | 372 |
| Payment of deferred financing costs | NaN | 0 | NaN | NaN |
| Net cash (used in) provided by financing activities | -52,804 | 2,546 | 6,530 | 2,988 |
| Effect of exchange rate changes on cash and cash equivalents | 233 | -322 | 64 | 286 |
| Net increase in cash and cash equivalents | 33,189 | 7,967 | 6,727 | 13,927 |
| Cash and cash equivalents, beginning of period | 62,406 | 54,439 | 33,785 | NaN |
| Cash and cash equivalents, end of period | 95,595 | 62,406 | 54,439 | NaN |